U.S.-made research peptides where specified. For research use only.
SRP DATABASE ACCESS
What are you researching?
Press ESC to close
SRP Research Library / Research Trials
Research in progress. Evidence comes next.
Follow SRP samples submitted to Freedom Labs. We share the testing stage here and will add the laboratory reports when they are available. Results are not yet published.
2 testing projects5 submitted vialsUpdated October 4, 2026
● TESTING IN PROGRESSSTUDY 01
RTZ-GLP3 10 mgRTZ-GLP3 30 mgRTZ-GLP3 60 mg
Freedom Labs • Laboratory testing
RTZ-GLP3: 10, 30 & 60 mg
Three vial strengths submitted for laboratory evaluation. RTZ-GLP3 is SRP’s catalogue name for retatrutide.
10 mg30 mg60 mg
REQUESTED ✓ Complete
AT THE LAB ✓ Received
TESTING In progress
REPORT Pending
Study details
One vial of each listed strength submitted.
Current stage: at the laboratory, testing in progress.
Methods, conditions and scope will be documented with the laboratory report.
No conclusions about stability, degradation or differences between strengths are available yet.
Laboratory report awaiting publication
● TESTING IN PROGRESSSTUDY 02
NAD+ 1,000 mgNAD+ 2,000 mg
Freedom Labs • Laboratory testing
NAD+: 1,000 & 2,000 mg
Does NAD+ degrade despite amber glass? SRP submitted its 1,000 mg and 2,000 mg NAD+ products, each in a 10 mL amber vial, to Freedom Labs to investigate this question. Testing is underway and the report is pending.
1,000 mg2,000 mg
REQUESTED ✓ Complete
AT THE LAB ✓ Received
TESTING In progress
REPORT Pending
Study details
One 1,000 mg vial and one 2,000 mg vial submitted.
Current stage: at the laboratory, testing in progress.
Protocol and testing conditions will be added when confirmed.
Both submitted NAD+ vials use amber glass. This project examines degradation, not clear versus amber packaging. Product images illustrate SRP packaging, not laboratory sample photographs.
Laboratory report awaiting publication
Reports first. Conclusions after.
These are laboratory testing projects, not human or animal clinical trials. Status is based on SRP’s submission update. Testing in progress does not establish a passing result, safety, efficacy or suitability for human use.
